Molecular Imaging ([18F]NOS or Florbetaben PET/CT Scan) for the Diagnosing of Amyloidosis

Inclusion Criteria

• Have an established diagnosis of amyloid light-chain (AL) amyloidosis based on standard criteria
• Have cardiac involvement as defined by all of the following: * Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure * Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole > 12 mm in the absence of other causes (e.g. severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening * NT-proBNP >= 650 pg/mL
• Participants should fall into one of the following 2 categories: * Treatment-naive or have completed no more than 1 cycle of initial therapy, OR * Relapsed after 1 or more prior therapies, and at least 6 months from last treatment
• Have serum free light chain (FLC) differential (defined as amyloid-forming FLC minus non-amyloid-forming FLC) >= 50 mg/L
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion Criteria

• Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer
• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
• Less than 6 months life expectancy as deemed by the treating physician